[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537236":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":10,"centralContacts":46,"locations":56,"responsibleParty":216,"collaborators":218,"id":227,"slug":228,"hasResults":229,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":10,"eligibilityCriteria":233,"healthyVolunteers":234,"sex":235,"minAge":236,"maxAge":237,"enrollmentInfo":238,"targetDuration":10,"studyType":241,"phases":10,"briefSummary":242,"conditions":243,"keywords":248,"overallStatus":59,"whyStopped":10,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":262},{"fullName":5,"class":6},"University of Latvia","OTHER",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Protocol I",null,"H. pylori positive patients who will be treated by bismuth-based quadruple therapy.\n\nParticipating centers: KBC Rijeka, Croatia; KBC Zagreb, Croatia; Beacon Hospital, Ireland; Uniwersytet medyczny we Wrocławiu, Poland; UMF Cluj-Napoca, Romania; NIJZ, Slovenia",[13],"Drug: Bismuth-based quadruple therapy",{"label":15,"type":10,"description":16,"interventionNames":17},"Protocol II","In case there will be a treatment failure after bismuth-based quadruple therapy, the remaining patients with a positive infection will be referred to a levofloxacin based quadruple therapy.\n\nParticipating centers: KBC Rijeka, Croatia; KBC Zagreb, Croatia; Beacon Hospital, Ireland; Uniwersytet medyczny we Wrocławiu, Poland; UMF Cluj-Napoca, Romania; NIJZ, Slovenia",[18],"Drug: Levofloxacin-based quadruple therapy",{"label":20,"type":10,"description":21,"interventionNames":22},"Standard triple therapy","H. pylori positive participants who will offered standard triple therapy.\n\nParticipating center: University of Latvia, Latvia",[23],"Drug: Standard triple therapy",{"label":25,"type":10,"description":26,"interventionNames":27},"Second line treatment - levofloxacin-based","In case there will be a treatment failure after standart triple therapy, the remaining patients with a positive infection will be referred to a second line treatment\n\nParticipating center: University of Latvia, Latvia",[28],"Drug: Levofloxacin-based triple",[30,35,39,42],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"DRUG","Bismuth-based quadruple therapy","Participants who are positive with H. pylori will receive bismuth-based quadruple therapy:\n\nAntibiotic 1 - Amoxicillin 4 x 500 mg or Clarithromycin 2 x 400 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg.",[9],{"type":31,"name":36,"description":37,"armGroupLabels":38,"otherNames":10},"Levofloxacin-based quadruple therapy","In case there will be a treatment failure after Protocol I is completed, the remaining patients with a positive infection will be referred to a secondary treatment:\n\nAntibiotic 1 - Levofloxacin 1 x 500 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg.",[15],{"type":31,"name":20,"description":40,"armGroupLabels":41,"otherNames":10},"Participants who are positive for H. pylori will receive a standard triple therapy:\n\nAntibiotic 1 - Amoxicillin 2 x 1000 mg, Antibiotic 2 - Clarithromycin 2 x 500 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg.",[20],{"type":31,"name":43,"description":44,"armGroupLabels":45,"otherNames":10},"Levofloxacin-based triple","Participants with treatment failure will be recommended second line treatment - levofloxacin-based:\n\nAntibiotic 1 - Levofloxacin 2 x 500 mg, Antibiotic 2 - Amoxicillin 2 x 1000 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg",[25],[47,52],{"name":48,"role":49,"phone":50,"phoneExt":10,"email":51},"Principal Investigator of the Study - Bojan Tepeš (National Institute of Public Health, Slovenia), Prof., MD","CONTACT","0038641325916","bojan.tepes@siol.net",{"name":53,"role":49,"phone":54,"phoneExt":10,"email":55},"Tatjana Kofol Bric (National Institute of Public Health, Slovenia), MD","0038612441484","Tatjana.Kofol@nijz.si",[57,88,102,128,150,174,196],{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"University Hospital Centre Zagreb","RECRUITING","Zagreb","City of Zagreb","10000","Croatia","HR",{"type":66,"coordinates":67},"Point",[68,69],15.97798,45.81444,{"lat":69,"lon":68},[72,76,80,82,85,87],{"name":73,"role":49,"phone":74,"phoneExt":10,"email":75},"Masa Cavlina Sevo, MD","00385995900847","masa.cavlina@gmail.com",{"name":77,"role":49,"phone":78,"phoneExt":10,"email":79},"Mirjana Kalauz, Asst. Prof.","0038598519088","mirjanakalauz1@gmail.com",{"name":77,"role":81,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"name":83,"role":84,"phone":10,"phoneExt":10,"email":10},"Pave Markos, MD, PhD","SUB_INVESTIGATOR",{"name":86,"role":84,"phone":10,"phoneExt":10,"email":10},"Tihomir Bradic, MD",{"name":73,"role":84,"phone":10,"phoneExt":10,"email":10},{"facility":89,"status":59,"city":90,"state":10,"zip":91,"country":63,"countryCode":64,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Clinical Hospital Center Rijeka","Rijeka","51000",{"type":66,"coordinates":93},[94,95],14.44241,45.32673,{"lat":95,"lon":94},[98],{"name":99,"role":49,"phone":100,"phoneExt":10,"email":101},"Sandra Milic, MD","0038551658122","smilic05@gmail.com",{"facility":103,"status":59,"city":104,"state":10,"zip":105,"country":106,"countryCode":107,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"Beacon Hospital","Dublin","D18 AK68","Ireland","IE",{"type":66,"coordinates":109},[110,111],-6.24889,53.33306,{"lat":111,"lon":110},[114,118,122,124,126],{"name":115,"role":49,"phone":116,"phoneExt":10,"email":117},"Charlene Deane, MB Bch BAO, MSc","00353879114305","charlene.deane@beaconhospital.ie",{"name":119,"role":49,"phone":120,"phoneExt":10,"email":121},"Ruth Pilkington, MB BcH BAO","0035312937521","ruth.pilkington@beaconhospital.ie",{"name":123,"role":81,"phone":10,"phoneExt":10,"email":10},"Colm O Morain, MD, MB BcH BAO, FRCPI",{"name":125,"role":84,"phone":10,"phoneExt":10,"email":10},"Orlaith Kelly, PHD, MB BcH",{"name":127,"role":84,"phone":10,"phoneExt":10,"email":10},"Charlene Deane, MB Bch BAO, MSc, MRCP",{"facility":129,"status":130,"city":131,"state":10,"zip":132,"country":133,"countryCode":134,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Clinical and Preventive Medicine of the University of Latvia","NOT_YET_RECRUITING","Riga","LV1079","Latvia","LV",{"type":66,"coordinates":136},[137,138],24.10589,56.946,{"lat":138,"lon":137},[141,145,146,148],{"name":142,"role":49,"phone":143,"phoneExt":10,"email":144},"Marcis Leja, MD, PhD","371+29497500","marcis.leja@lu.lv",{"name":142,"role":81,"phone":10,"phoneExt":10,"email":10},{"name":147,"role":84,"phone":10,"phoneExt":10,"email":10},"Danute Razuka Ebela, MD, PhD",{"name":149,"role":84,"phone":10,"phoneExt":10,"email":10},"Linda Mezmale, MD",{"facility":151,"status":59,"city":152,"state":10,"zip":153,"country":154,"countryCode":155,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"Wroclaw Medical University","Wroclaw","50-367","Poland","PL",{"type":66,"coordinates":157},[158,159],17.03006,51.10286,{"lat":159,"lon":158},[162,166,170,172],{"name":163,"role":49,"phone":164,"phoneExt":10,"email":165},"Katarzyna Malinowska","00487178417 99","k.malinowska@umw.edu.pl",{"name":167,"role":49,"phone":168,"phoneExt":10,"email":169},"Elzbieta Olejnik","00717841666","elzbieta.olejnik@umw.edu.pl",{"name":171,"role":81,"phone":10,"phoneExt":10,"email":10},"Katarzyna Neubauer, MD, PhD, Assoc. Prof.",{"name":173,"role":84,"phone":10,"phoneExt":10,"email":10},"Radoslaw Kempinski, MD, PhD",{"facility":175,"status":59,"city":176,"state":177,"zip":178,"country":179,"countryCode":180,"cosmosGeoPoint":181,"geoPoint":185,"contacts":186},"Iuliu Hatieganu University of Medicine and Pharmacy","Cluj-Napoca","Cluj","400003","Romania","RO",{"type":66,"coordinates":182},[183,184],23.6,46.76667,{"lat":184,"lon":183},[187,191,195],{"name":188,"role":49,"phone":189,"phoneExt":10,"email":190},"Dan Lucian Dumitrascu, Prof","0040722756475","ddumitrascu@umfcluj.ro",{"name":192,"role":49,"phone":193,"phoneExt":10,"email":194},"Radu Farcas, MD, PhD student","0040757554422","radufr@gmail.com",{"name":192,"role":84,"phone":10,"phoneExt":10,"email":10},{"facility":197,"status":59,"city":198,"state":10,"zip":199,"country":200,"countryCode":201,"cosmosGeoPoint":202,"geoPoint":206,"contacts":207},"National Institute of Public Health, Slovenia","Ljubljana","1000","Slovenia","SI",{"type":66,"coordinates":203},[204,205],14.50513,46.05108,{"lat":205,"lon":204},[208,212,214],{"name":209,"role":49,"phone":210,"phoneExt":10,"email":211},"Mitja Oblak, MSc","0038612441541","Mitja.Oblak@nijz.si",{"name":213,"role":49,"phone":54,"phoneExt":10,"email":55},"Tatjana Kofol, MD",{"name":215,"role":81,"phone":10,"phoneExt":10,"email":10},"Bojan Tepeš, prof., MD",{"type":217,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[219,220,222,223,224,225],{"name":89,"class":6},{"name":221,"class":6},"Clinical Hospital Centre Zagreb",{"name":103,"class":6},{"name":151,"class":6},{"name":175,"class":6},{"name":197,"class":226},"OTHER_GOV","100537236","h-pylori-screen-and-treat-study-in-a-population-of-young-adults-100537236",false,"NCT06275204","H. Pylori Screen-and-treat Study in a Population of Young Adults","Multicentric Transnational H. Pylori Screen-and-treat Study in a Population of Young Adults","Inclusion Criteria:\n\n* Young adults (generally 30 - 34 years of age)\n\nExclusion Criteria:\n\n* Patients with mental or developmental limitations who cannot provide a fully-informed consent to participate (based on the assessment from research or patient's personal physician team)\n* Previously treated H. pylori infection\n* History of partial or total gastric resection due to benign or malign lesions",true,"ALL","30 Years","34 Years",{"count":239,"type":240},6800,"ESTIMATED","OBSERVATIONAL","Gastric cancer remains a major challenge to public health on a global scale. H. pylori related cancer burden contributes to the largest proportion of cancer cases attributable to infections in Europe. Considering its absolute burden and persisting disparities, in addition to the substantial prevalence of H. pylori infection worldwide that is treatable, gastric cancer is a logical target for urgent action for prevention. Population-based H. pylori test-and-treat has therefore been proposed as a strategy for gastric cancer prevention. To fill the gaps in knowledge about gastric cancer prevention through H. pylori screening and eradication in younger adults, a study of a population-based H. pylori test-and-treat strategy in Ireland, Croatia, Latvia, Poland, Romania and Slovenia.\n\nMain goals of this study are to assess future program processes, feasibility, acceptability and effectiveness. In total of 6,800 adults aged 30-34 will be tested for H. pylori infection. They will be randomly selected to represent the chosen population and invited to participate in the study based on informed consent. Confirmed infections will be treated by available combined therapy in line with treatment guidelines and the success of eradication will be retested during a control check-up.\n\nPatients who will provide their consent to participate will undertake an interview about the risk factors in early childhood and their habits regarding alcohol consumption and use of tobacco. Compliance to testing and treatment, treatment results, adverse effects and reasons for dropping out will be additionally monitored. Gathered data will be analysed in alignment with our research questions. The investigators will disseminate reports and present the results to both the general public and the scientific community in order to foster future developments in gastric cancer prevention.",[244,245,246,247],"Gastric Cancer","H Pylori Infection","H Pylori Eradication","H-pylori",[249,250,251,252],"H. pylori","gastric cancer","eradication therapy","screening","2024-03-03",{"date":255,"type":256},"2024-03-05","ACTUAL",{"date":258,"type":240},"2024-03-04",{"date":260,"type":240},"2026-12-01",{"name":5,"class":6},7]